Senescent cells, which are characterized by irreversible damage and an inflammatory secretome, are considered a key driving force behind many age-related diseases. Due to a failure in immune surveillance, senescent cells accumulate and impact their local environment by inducing inflammation and promoting extracellular matrix remodeling, thus resulting in a myriad of metabolic and fibrotic consequences. Therefore, enabling the removal of senescent cells dramatically ameliorates disease pathologies in many age-related diseases, leading to overall improvements in health-span.
At Deciduous Therapeutics, we have discovered novel molecules that can activate a critical endogenous immune surveillance mechanism to selectively remove senescent cells and thereby treat several classes of age-related diseases.
Company Details
- Employees
- 12
- Address
- 953 Indiana St, San Francisco,california 94107,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.deciduoustx.com
- Keywords
- in immunology and drug development.
- HQ
- San Francisco, California
Deciduous Therapeutics Questions
Deciduous Therapeutics's website is http://www.deciduoustx.com
Deciduous Therapeutics's LinkedIn profile is https://www.linkedin.com/company/deciduous-therapeutics
Deciduous Therapeutics has
12 employees.
View email and phone details for 12
employees at Deciduous Therapeutics.
Deciduous Therapeutics's industry is
Biotechnology Research
Deciduous Therapeutics's top competitors are
Switch Therapeutics,
Denali Therapeutics,
Serna Bio,
Kerna Labs,
Retro Biosciences,
Mbc Biolabs,
Antios Therapeutics,
Montara Therapeutics, Inc.,
Xaira Therapeutics,
Birdwood Therapeutics.
Deciduous Therapeutics's categories are Biotechnology Research
